Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Professor Kumlesh Dev

Professor (Physiology)

Professor (Trinity Inst. of Neurosciences (TCIN))

  Drug Targets   Glutamate Receptors   Multiple Sclerosis   Neuroscience   Parkinson's Disease   Protein-Protein Interactions   Receptor Trafficking   Sphingosine 1-phosphate receptors
Details Date
Representative Director Ireland, Venture Valuation AG, Zurich, Switzerland
Details Date From Date To
Board Member of Journal of Biological Chemistry
Editorial Board Member of Canadian Journal of Pure and Applied Sciences
Velasco-Estevez M, Mampay M, Boutin H, Chaney A, Warn P, Sharp A, Burgess E, Moeendarbary E, Dev KK, Sheridan GK., Infection Augments Expression of Mechanosensing Piezo1 Channels in Amyloid Plaque-Reactive Astrocytes., Front Aging Neurosci, 10:332. doi: 10.3389, 2018, Journal Article, PUBLISHED
Rutkowska, A. and Shimshek, D.R. and Sailer, A.W. and Dev, K.K., EBI2 regulates pro-inflammatory signalling and cytokine release in astrocytes, Neuropharmacology, 133, 2018, p121-128 , Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
O'Sullivan, S.A. and O'Sullivan, C. and Healy, L.M. and Dev, K.K. and Sheridan, G.K., Sphingosine 1-phosphate receptors regulate TLR4-induced CXCL5 release from astrocytes and microglia, Journal of Neurochemistry, 2018, Notes: [cited By 0; Article in Press], Journal Article, PUBLISHED  DOI
Dutta, P. and Dargahi, L. and O'Connell, K.E. and Bolia, A. and Ozkan, B. and Sailer, A.W. and Dev, K.K., A novel modelling mechanism of PAEL receptor and GABARAPL2 interaction involved in Parkinson's disease, Neuroscience Letters, 673, 2018, p12-18 , Notes: [cited By 0], Journal Article, PUBLISHED  DOI
O'Sullivan S, Dev K.K, Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases, Neuropharmacology, 113, 2017, p597 - 607, Journal Article, PUBLISHED  DOI  URL
O'Sullivan S.A, Velasco-Estevez M, Dev K.K, Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors, GLIA, 2017, p23148-, Journal Article, PUBLISHED  DOI  URL
Dev K.K, Irving A.J, Lipid sensing G protein-coupled receptors in the CNS, Neuropharmacology, 113, 2017, p595 - 596, Journal Article, PUBLISHED  DOI  URL
Rutkowska, A. and Sailer, A.W. and Dev, K.K., EBI2 receptor regulates myelin development and inhibits LPC-induced demyelination, Journal of Neuroinflammation, 14, (1), 2017, p250-, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
Misslin, C. and Velasco-Estevez, M. and Albert, M. and O†Sullivan, S.A. and Dev, K.K., Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination, PLoS ONE, 12, (11), 2017, e0187217-, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI
O'Sullivan, S.A. and Dev, K.K., The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices, Journal of Neuroinflammation, 14, (1), 2017, p159-, Notes: [cited By 0], Journal Article, PUBLISHED  TARA - Full Text  DOI

Page 1 of 9


Research is based on investigating mechanisms that control receptor surface expression and thereby receptor function. With an interest in Multiple Sclerosis and Parkinson's Disease, we are investigating surface expression of receptors that are drug targets for these diseases, including sphingosine 1-phosphate receptors (S1P-R), parkin-associated endothelial like receptor (PAEL-R) and the interleukin 2 receptor (IL2-R). Our approach is to engineer, formulate and chemically re-design competitive blocking peptides and discover small molecular weight compounds, which alter receptor surface expression and function in vivo. Development of such agents permits cell-selective receptor modulation and the regulation of orphan receptors or difficult-to-target receptors. We are funded in kind and in part by Trinity College Dublin, Science Foundation Ireland, Health Research Board Ireland, Enterprise Ireland, The Wellcome Trust, Lundbeck, Actelion, Servier and Novartis.